Considering that prostate-specific membrane antigen (PSMA)-PET/computed tomography (PET/CT) is a vital method for diagnosing and treatment planning in advanced prostate cancer (6), obtaining additional information using radiomic features (RFs) is a highly desirable approach, especially when it comes to treatment planning (7). This evidence concerns the gene FOLH1 and prostate carcinoma.